Get the Stockscreener App
25.06
5.04%
-1.33
Pre-market:
25.29
0.23
+0.92%
Arcus Biosciences Inc stock is traded at $25.06, with a volume of 1.99M.
It is down -5.04% in the last 24 hours and down -16.80% over the past month.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
See More
Previous Close:
$26.39
Open:
$26.2
24h Volume:
1.99M
Relative Volume:
1.43
Market Cap:
$3.19B
Revenue:
$236.00M
Net Income/Loss:
$-369.00M
P/E Ratio:
-7.8736
EPS:
-3.1828
Net Cash Flow:
$-489.00M
1W Performance:
-1.88%
1M Performance:
-16.80%
6M Performance:
+23.75%
1Y Performance:
+100.32%
1-Day Range:
$24.42
$26.49
1-Week Range:
$24.42
$27.90
52-Week Range:
$12.15
$31.73
Arcus Biosciences Inc Stock (RCUS) Company Profile
Name
Arcus Biosciences Inc
Sector
Industry
Phone
(510) 694-6200
Address
3928 POINT EDEN WAY, HAYWARD, CA
Compare RCUS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCUS
Arcus Biosciences Inc
|
25.06 | 3.19B | 236.00M | -369.00M | -489.00M | -3.1828 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-13-26 | Upgrade | Goldman | Neutral → Buy |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-26-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-21-24 | Initiated | H.C. Wainwright | Neutral |
| Oct-08-24 | Initiated | Wells Fargo | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Nov-23-20 | Initiated | Evercore ISI | Outperform |
| Apr-03-20 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Sep-27-19 | Initiated | Mizuho | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Oct-09-18 | Initiated | Wedbush | Outperform |
| Apr-09-18 | Initiated | Citigroup | Buy |
| Apr-09-18 | Initiated | Goldman | Neutral |
| Apr-09-18 | Initiated | Leerink Partners | Outperform |
View All
Arcus Biosciences Inc Stock (RCUS) Latest News
Arcus Biosciences Announces New Employment Inducement Grants - ca.finance.yahoo.com
Arcus Biosciences, Inc. (RCUS) Stock forecasts - Yahoo Finance Singapore
Arcus Biosciences stock trades 16.8 percent below yearly high - AD HOC NEWS
Arcus Biosciences, Inc. (RCUS) Stock Forecasts - finance.yahoo.com
(RCUS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
RCUS Looks 292.6% Overvalued on GF Value™ - GuruFocus
Cantor Fitzgerald reiterates Arcus Biosciences stock rating By Investing.com - Investing.com Canada
Cantor Fitzgerald reiterates Arcus Biosciences stock rating - Investing.com
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy - finance.yahoo.com
Arcus Biosciences stock holds steady as investors eye latest clinical and earnings signals - AD HOC NEWS
Arcus Biosciences (RCUS) Stock Analysis: Exploring a 51.72% Potential Upside in Biotechnology - DirectorsTalk Interviews
Arcus Biosciences stock gains on TD Cowen buy rating - Investing.com
Arcus Biosciences stock gains on TD Cowen buy rating By Investing.com - Investing.com Canada
Why is Arcus Biosciences stock rallying today? By Investing.com - Investing.com UK
RCUS Initiates Coverage On by TD Cowen -- Rating Set to Buy - GuruFocus
Arcus Biosciences stock initiated at Buy by TD Cowen on RCC drug - Investing.com Australia
TD Cowen Initiates Arcus Biosciences at Buy - marketscreener.com
RCUS: Pivotal ARC-20 data and phase III trials aim to establish casdatifan as a market leader in RCC - TradingView
(RCUS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Arcus Biosciences Slides as Investors Weigh Pipeline Overhang Ahead of Next Data Catalysts - Quiver Quantitative
Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Cooper Co (COO) and Arcus Biosciences (RCUS) - The Globe and Mail
Arcus Biosciences at cantor global healthcare conference: casdatifan in focus By Investing.com - Investing.com Canada
Arcus Biosciences at cantor global healthcare conference: casdatifan in focus - Investing.com India
One new employee can buy 26,350 Arcus shares. Arcus also awarded rights to 13,200 shares. - Stock Titan
Arcus Biosciences at Citi summit: casdatifan data loom large By Investing.com - Investing.com India
Following VIRO 2025 Success, Arcus Biosciences Continues Partnership in 2026 - oncodaily.com
Truist raises Arcus Biosciences stock price target on trial data By Investing.com - Investing.com South Africa
RCUS Reiterated by Truist Securities -- Price Target Raised to $40 - GuruFocus
RCUS Q2 2026 Earnings: Narrower Loss Beats Estimates by 21.41%Slow Growth Warning - careplusvn.com
Understanding the Setup: (RCUS) and Scalable Risk - Stock Traders Daily
Arcus Biosciences Inc. (RCUS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Arcus Biosciences Inc. (RCUS) Peer Comparison – Compare with Others - Value Research
Arcus Biosciences Inc. (RCUS) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Arcus Biosciences will take part in 3 New York conferences in September - Stock Titan
Why Arcus Biosciences (RCUS) Is Getting Attention Today - Sahm
Arcus Biosciences to Participate in Three Upcoming Investor Conferences - finance.yahoo.com
Arcus Biosciences CAO Azoy sells $84,810 in stock By Investing.com - Investing.com Nigeria
Arcus Biosciences CAO Azoy sells $84,810 in stock - Investing.com India
Arcus Biosciences (NASDAQ: RCUS) CAO sells shares from option plan - stocktitan.net
Arcus (RCUS) Range: Rises 2.78% to $30.34 in the Latest Session; Level Watch: Price Remains Between $28.82 Support and $31.86 Resistance on the DayVWAP Bounce - vinanet.vn
Arcus Biosciences (RCUS) officer eyes sale after June plan trades - Stock Titan
Arcus Biosciences (RCUS) Stock Looks Strong On Returns But Stretched On Sales - Sahm
Investigation launched into Arcus Biosciences o... - Pluang
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm - Morningstar
Handelsbanken Fonder AB Takes $1.20 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
What Arcus Biosciences (RCUS)'s Steep Revenue Drop and 2026 Guidance Cut Means For Shareholders - webull.com
Arcus Biosciences Inc (RCUS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Arcus Biosciences (RCUS) Advances 2.15% as Oncology Pipeline Momentum BuildsEMA Signal - vinanet.vn
Arcus Biosciences (RCUS) Reported Q2 2026 Results, Is The Stock A Bargain? - Sahm
Arcus Biosciences (RCUS) Gains Nearly 2% as Shares Trade Near Key Resistance at $30.90Call Dominated - vinanet.vn
Arcus Biosciences, Inc. Stock 12‑Month Price Target Raised to $38.82, Implies 35% Upside - TradingView
Arcus Biosciences Inc Stock (RCUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):